表紙
市場調查報告書

疾病分析:哮喘預測和市場分析

Disease Analysis: Asthma - Forecast and Market Analysis

出版商 Datamonitor Healthcare 商品編碼 955898
出版日期 內容資訊 英文 82 Pages
商品交期: 最快1-2個工作天內
價格
疾病分析:哮喘預測和市場分析 Disease Analysis: Asthma - Forecast and Market Analysis
出版日期: 2020年08月10日內容資訊: 英文 82 Pages
簡介

哮喘是一種慢性呼吸系統疾病,其特徵是反覆發作的喘氣,咳嗽,呼吸急促等,這是由於諸如運動,接觸過敏原和刺激物,天氣變化和病毒性呼吸道感染等因素引起的。將被觸發。發作是由於支氣管內膜腫脹導致氣道變窄,並減少了進出肺部的氣流。曾經被認為是單一疾病,現在被視為導致症狀的各種病理生理過程的表型的集合。

據估計,2018年將有約3.436億44歲以下的人患有哮喘病,預計到2027年將增至3.637億。

在哮喘領域批准的大多數藥物是吸入型小分子藥物,但是一些新批准的藥物包括通過注射給藥的生物製劑。

本報告對全球哮喘市場進行了調查,包括疾病背景,治療,流行病學,正在開發的藥物,主要的管制運動,許可和資產收購運動以及臨床試驗。它提供有關情況,藥物評估模型,市場動態,未來趨勢等的信息,以及分析師和意見領袖的觀點。

目錄

概述

疾病背景

  • 定義
  • 患者分類

治療

  • 主要藥理治療
  • 逐步治療
  • 基於SABA的鎮痛藥
  • ICS和LABA,長期管理藥物的核心
  • 結合使用其他治療
  • 高度個性化嚴重哮喘的其他治療
  • 推翻傳統哮喘治療的新療法
  • COVID-19哮喘管理建議

流行病學

  • 患病率調查方法

非處方藥

管道醫學

主要監管動向

  • Teva推出乾粉數字吸入器ProAir
  • 諾華三合一Enerzair獲得歐盟批准
  • 由Enerzair和Atectura在日本批准
  • Cipla為Advair櫃檯產品提交ANDA
  • Mylan在加拿大推出Advair競爭對手產品
  • 英國的NICE不贊成賽諾菲的Dupixent治療哮喘
  • 美國FDA指示在Singulair中顯示有關神經精神病事件的警告文字
  • 加拿大描述了口服生物仿製產品所需的研究
  • GSK的Trelegy成為第一個三重吸入方案
  • 諾華製藥準備振興呼吸事業
  • 安全通信:FDA小組提供有關Singulair風險的選項

成功的可能性

許可和資產收購協議

  • 基耶西和拜耳在中國共同銷售呼吸道醫學
  • GSK削減消費品牌產品的銷售
  • Yuhan與GI Innovation合作開發下一代抗過敏藥
  • Iconovo和Amneal合作開發Symbicort櫃檯產品 [li] 4000萬美元用於LEO,新皮炎和哮喘的候選藥物
  • Alvogen通過多份合同促進自主品牌產品的銷售

臨床試驗情況

  • 按狀態贊助
  • 按階段贊助
  • 最近事件

藥物評估模型

  • ICS
  • ICS/LABA
  • ICS/LABA/LAMA
  • 其他口服藥物類別
  • 生物製劑

市場動態

未來趨勢

  • 產生高利潤的昂貴生物製劑
  • ICS/LABA類保持主導地位
  • 對LAMA作用的懷疑可能會延遲三方療法的引入

共識預測

最近發生的事件和分析師的觀點

  • QAW039(2019年12月16日)
  • Seliforan(2019年12月2日)
  • Masitinib(2019年11月7日)
  • QAW039(2019年10月22日)
  • Atectura Breezhaler (2019年9月30日)
  • Enerzair Breezhaler(2019年9月30日)
  • Trimbow(2019年9月30日)
  • REGN3500(2019年6月21日)
  • Atectura Breezhaler (2019年5月30日)
  • Enerzair Breezhaler(2019年5月22日)
  • Trelegy Ellipta (2019年5月2日)

即將發生的重大事件

主要專家的意見

參考

  • 處方信息

附錄

圖表列表

目錄
Product Code: DMKC0215933

Defintion

Asthma is a chronic respiratory condition characterized by recurrent wheezing, coughing, and breathlessness, which occur in acute events known as exacerbations. Often triggered by factors such as exercise, allergen or irritant exposure, change in weather, or viral respiratory infections, these flare-ups can vary significantly in frequency and severity. Attacks consist of swelling of the lining of the bronchial tubes, which narrows airways and results in a reduction of airflow into and out of the lungs. Historically considered to be a single disease, asthma is now viewed more as an overlapping assemblage of individual phenotypes with various underlying pathophysiological processes leading to symptoms.

Latest key takeaways

Datamonitor Healthcare estimates that in 2018, there were approximately 343.6 million prevalent cases of asthma in individuals aged up to 44 years worldwide, and forecasts that number to increase to 363.7 million prevalent cases by 2027.

The GINA treatment strategy released in 2019 included an important change disrupting a fundamental practice in mild asthma management. Treatment with a short-acting beta 2 agonist (SABA) alone is no longer recommended for adults and adolescents with asthma. While short-acting bronchodilators may provide symptom relief for patients, they remain at risk for severe exacerbations.

The majority of approved drugs in the asthma space are inhaled small molecules, while several newer approvals show a shift towards development of injectable biologics.

Since its launch as the first fixed-dose combination (FDC) of an inhaled corticosteroid (ICS) and a long-acting beta 2 agonist (LABA), GlaxoSmithKline's Advair has become a well-established gold-standard therapy in asthma. However, generic competition in Europe, and more recently in the US, marks the end of this successful history.

Novartis has ended development of its asthma drug fevipiprant following data which showed that the once-daily pill was not effective.

The convenience of pipeline ICS/LABA/long-acting muscarinic antagonist (LAMA) triple FDC therapies will only marginally increase the overall use of the LAMA drug class as physicians remain skeptical about the role of LAMAs in asthma.

In 2020, key catalysts to anticipate include topline results from Phase III studies for tezepelumab and masitinib.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

  • Latest key takeaways

DISEASE BACKGROUND

  • Definition
  • Patient segmentation

TREATMENT

  • Main pharmacological treatments are categorized as controllers or relievers
  • Treatment guidelines recommend step-up therapy
  • Reliever medications have traditionally consisted of SABAs
  • Controller medications are dominated by ICSs and LABAs
  • Concomitant use of additional treatments may be considered
  • Add-on treatment for severe asthma has become highly personalized
  • New recommendations upend decades of routine asthma management
  • COVID-19 recommendations for asthma management

EPIDEMIOLOGY

  • Prevalence methodology

MARKETED DRUGS

PIPELINE DRUGS

KEY REGULATORY EVENTS

  • Teva Launches ProAir Dry Powder Digital Inhaler
  • Novartis Triple Combo Enerzair Gets EU OK For Asthma
  • Japan Nods For Enerzair And Atectura For Asthma
  • Cipla Files ANDA For Advair Rival
  • Mylan Launches Advair Rival In Canada
  • England's NICE Says No To Sanofi's Dupixent For Asthma
  • US FDA Orders Singulair Boxed Warning On Neuropsychiatric Events Despite 'Limited' Evidence
  • Canada Explains Studies Needed For Subsequent-Entry Orally Inhaled Products
  • GSK's Trelegy On Track To Be First Triple Inhaled Regimen For Asthma
  • Novartis Primed To Re-Energize Respiratory Business, Rivals Close In
  • Safety Communications: US FDA Panel Offers Menu Of Options For Singulair's Risks

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Chiesi Gets Bayer To Co-Promote Respiratory Drugs In China
  • GSK Sells Lesser Consumer Brands With Little Fanfare As Part Of Major Plan For Global Lead
  • Yuhan Partners With GI Innovation On Next-Generation Allergy Treatment
  • Iconovo And Amneal Collaborate On Symbicort Rival
  • LEO Pays $40m For Novel Dermatitis, Asthma Candidate
  • Alvogen Advances Its Branded Offering Via Agreements

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

DRUG ASSESSMENT MODEL

  • ICSs
  • ICS/LABAs
  • ICS/LABA/LAMAs
  • Other oral classes
  • Biologics

MARKET DYNAMICS

FUTURE TRENDS

  • High biologic prices will translate to high revenues, despite restricted prescribing
  • The ICS/LABA class will remain dominant by patient share, as first-generation products lose share to follow-on products and generics
  • Skepticism regarding the role of LAMAs in asthma may blunt uptake of triple therapies

CONSENSUS FORECASTS

RECENT EVENTS AND ANALYST OPINION

  • QAW039 for Asthma (December 16, 2019)
  • Seliforant for Asthma (December 2, 2019)
  • Masitinib for Asthma (November 7, 2019)
  • QAW039 for Asthma (October 22, 2019)
  • Atectura Breezhaler for Asthma (September 30, 2019)
  • Enerzair Breezhaler for Asthma (September 30, 2019)
  • Trimbow for Asthma (September 30, 2019)
  • Multiple Drugs for Asthma (June 25, 2019)
  • REGN3500 for Asthma (June 21, 2019)
  • Atectura Breezhaler for Asthma (May 30, 2019)
  • Enerzair Breezhaler for Asthma (May 22, 2019)
  • Trelegy Ellipta for Asthma (May 2, 2019)

KEY UPCOMING EVENTS

KEY OPINION LEADER INSIGHTS

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of asthma, 2018-27
  • Figure 2: Overview of pipeline drugs for asthma in the US
  • Figure 3: Pipeline drugs for asthma, by company
  • Figure 4: Pipeline drugs for asthma, by drug type
  • Figure 5: Pipeline drugs for asthma, by classification
  • Figure 6: Probability of success in the asthma pipeline
  • Figure 7: Clinical trials in asthma
  • Figure 8: Top 10 drugs for clinical trials in asthma
  • Figure 9: Top 10 companies for clinical trials in asthma
  • Figure 10: Trial locations in asthma
  • Figure 11: Asthma trials status
  • Figure 12: Asthma trials sponsors, by phase
  • Figure 13: Datamonitor Healthcare's drug assessment summary for asthma
  • Figure 14: Market dynamics in asthma
  • Figure 15: Future trends in asthma
  • Figure 16: QAW039 for Asthma (December 16, 2019): Phase III - LUSTER 1, Phase III - LUSTER 2
  • Figure 17: Seliforant for Asthma (December 2, 2019): Related Drug - Trial Data
  • Figure 18: Masitinib for Asthma (November 7, 2019): Phase III - AB07015
  • Figure 19: QAW039 for Asthma (October 22, 2019): Phase III - ZEAL-1, Phase III - ZEAL-2
  • Figure 20: Atectura Breezhaler for Asthma (September 30, 2019): Phase III - PALLADIUM
  • Figure 21: Enerzair Breezhaler for Asthma (September 30, 2019): Phase III - IRIDIUM (w/QMF149)
  • Figure 22: Trimbow for Asthma (September 30, 2019): Phase III - TRIGGER , Phase III - TRIMARAN
  • Figure 23: REGN3500 for Asthma (June 21, 2019): Phase II - w/Dupilumab
  • Figure 24: Atectura Breezhaler for Asthma (May 30, 2019): Phase III - QUARTZ (vs. MF Twisthaler)
  • Figure 25: Enerzair Breezhaler for Asthma (May 22, 2019): Phase II - vs. Salmeterol/Fluticasone
  • Figure 26: Trelegy Ellipta for Asthma (May 2, 2019): Phase III - CAPTAIN
  • Figure 27: Key upcoming events in asthma

LIST OF TABLES

  • Table 1: Patient severity in asthma
  • Table 2: GINA treatment strategy for asthma
  • Table 3: Prevalent cases of asthma, 2018-27
  • Table 4: Marketed drugs for asthma
  • Table 5: Pipeline drugs for asthma
  • Table 6: Historical global sales, by drug ($m), 2015-19
  • Table 7: Forecasted global sales, by drug ($m), 2020-24
  • Table 8: QAW039 for Asthma (December 16, 2019)
  • Table 9: Seliforant for Asthma (December 2, 2019)
  • Table 10: Masitinib for Asthma (November 7, 2019)
  • Table 11: QAW039 for Asthma (October 22, 2019)
  • Table 12: Atectura Breezhaler for Asthma (September 30, 2019)
  • Table 13: Enerzair Breezhaler for Asthma (September 30, 2019)
  • Table 14: Trimbow for Asthma (September 30, 2019)
  • Table 15: Multiple Drugs for Asthma (June 25, 2019)
  • Table 16: REGN3500 for Asthma (June 21, 2019)
  • Table 17: Atectura Breezhaler for Asthma (May 30, 2019)
  • Table 18: Enerzair Breezhaler for Asthma (May 22, 2019)
  • Table 19: Trelegy Ellipta for Asthma (May 2, 2019)